Abstract: It is an object to provide an evaporative fuel processing apparatus capable of enhancing a purging efficiency by heating a part of activated charcoal which can be heated more effectively and also restraining an increase in temperature of the activated charcoal to prevent a deterioration in adsorbing performance, and restraining electricity consumption. Heating devices (16a) and (16b) are placed at almost the midpoints of the adsorption material layers (7a) and (7b) respectively in a canister (1) to heat an adsorption material (4) for a predetermined time before start of purging. Accordingly, heating the part hard to purge can prompt the purging, thereby enhancing the purging efficiency and increasing the adsorbing capacity. Furthermore, the heating is stopped during the purging, so that the increase in temperature of the adsorption material (4) can be prevented, thereby preventing a deterioration in adsorbing performance at the time of adsorption of evaporative fuel.

Abstract: A morpholine derivative represented by formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.3, which may be the same or different, each represent a hydrogen atom or a lower alkyl group; R.sup.2 represents a halogen atom; and the dotted line indicates an optional double bond. These compounds exhibit a selective 5-HT reuptake inhibitory activity and a selective 5-HT.sub.2 receptor antagonistic activity and useful as a therapeutic agent for depression, anxiety, etc. with reduced side effects.

Abstract: Pterin derivatives are described having the formula (I) ##STR1## wherein R represents a hydroxyphenyl group, a radioiodinated hydroxyphenyl group, a tyraminocarbonyl group, a radioiodinated tyraminocarbonyl group, a proteinocarbonyl group or a carboxy group; Q represents a straight or branched chain alkylene group having 1 to 6 carbon atoms; and R.sub.6 and R.sub.7 each represents a hydrogen, an alkyl group having from 1 to 6 carbon atoms, a hydroxyalkyl group having from 1 to 6 carbon atoms; and a radioimmunoassay method is described using a radioiodinated 4-hydroxy-2-tyraminopteridine derivative or a radioiodinated 4-hydroxy-2-tyraminocarbonylalkylaminopteridine derivative as the tracer.